MacroGenics (MGNX) Stock Price, News & Analysis

Company Overview

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies. The ADAPTIR platform enables the design of multi-specific antibodies with modular binding domains, allowing precise activation of immune cells. The Trident format supports the simultaneous targeting of three molecular entities, potentially improving selectivity and efficacy. These platforms underpin a diversified pipeline that spans oncology indications as well as immuno-oncology combinations and autoimmune disease targets.

Based in Rockville, Maryland, MacroGenics conducts its research and early development in the United States and collaborates with clinical trial centers across North America, Europe and Asia. Strategic partnerships with companies such as Merck, Servier and Kyowa Kirin have supported late-stage development, regulatory filings and potential commercialization in territories outside the United States. These alliances enhance the company’s ability to bring innovative therapies to a broader patient population.

Leadership at MacroGenics is headed by President and Chief Executive Officer Scott Koenig, who draws on extensive experience in oncology drug development to guide strategic and operational initiatives. The company’s governance is further strengthened by a scientific advisory board and an experienced management team, all of whom are committed to advancing novel antibody therapeutics through rigorous research and clinical evaluation.

Key Stats

• Today's Range: $1.83 to $1.93
• 50-Day Range: $1.44 to $2.02
• 52-Week Range: $0.99 to $5.10
• Volume: 562,366 shs
• Average Volume: 729,114 shs
• Market Capitalization: $115.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.60
• Consensus Rating: Hold

MacroGenics Stock Analysis - MarketRank™

MacroGenics scored higher than 83% of companies evaluated by MarketBeat, and ranked 156th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

Upside Potential

MacroGenics has a consensus price target of $3.60, representing about 96.7% upside from its current price of $1.83.

Amount of Analyst Coverage

MacroGenics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MacroGenics is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MacroGenics is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MacroGenics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.10% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in MacroGenics has recently decreased by 5.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MacroGenics does not currently pay a dividend.

Dividend Growth

MacroGenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.61

Percentage of Shares Shorted

6.10% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in MacroGenics has recently decreased by 5.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,515.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGNX Stock Analysis - Frequently Asked Questions

How have MGNX shares performed this year?

MacroGenics' stock was trading at $3.25 at the beginning of the year. Since then, MGNX stock has decreased by 43.7% and is now trading at $1.83.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.02. The biopharmaceutical company earned $22.24 million during the quarter, compared to analysts' expectations of $28.06 million. MacroGenics had a negative trailing twelve-month return on equity of 40.24% and a negative net margin of 21.99%.

Who are MacroGenics' major shareholders?

MacroGenics' top institutional shareholders include SG Americas Securities LLC (0.03%). Insiders that own company stock include Target N V Biotech, William K Heiden, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters.
View institutional ownership trends.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/23/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGNX
• CIK: 1125345
• Web: www.macrogenics.com
• Phone: (301) 251-5172
• Fax: 301-251-5321
• Employees: 430
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MacroGenics: $3.60
• High Price Target: $5.00
• Low Price Target: $2.00
• Potential Upside/Downside: +96.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.97 million
• Net Margins: -21.99%
• Pretax Margin: -21.36%
• Return on Equity: -40.24%
• Return on Assets: -14.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.26
• Quick Ratio: 5.02

Sales & Book Value

• Annual Sales: $149.96 million
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 63,210,000
• Free Float: 54,989,000
• Market Cap: $115.67 million
• Optionable: Optionable
• Beta: 1.61